An ancient tonic root valued as an immune supporter and debated longevity aid. Human evidence most consistently shows favorable shifts in immune and inflammation markers, plus add-on help in kidney disease, heart failure, and treatment-related fatigue. Its longevity claim moves a marker but not clearly how people feel or function. Generally well tolerated; mild digestive upset is the main effect. (Full Review)

Protocol

Tonic Dose (Root)

9–30 g/day

Dried-root decoction; 500 mg–2 g/day Western extract

Longevity Dose (TA-65)

10–50 mg/day

Purified cycloastragenol-standardized extract

Dosing

1–2× daily with food

Split dosing common; taken with food to reduce gastrointestinal upset

Time to effect

Immune & Inflammation

Weeks–months

Immune and inflammatory marker changes in trials

Telomere Length

6–12 months

Assessed in TA-65 studies

Benefits

High: Immune modulation and reduced inflammatory signaling

Medium: Renal protection in diabetic kidney disease; reduced cancer-related fatigue and improved quality of life; adjunctive support in heart failure

Low: Telomere lengthening

Speculative: Neuroprotection and cognitive aging; skin longevity and photoprotection; lifespan and healthspan extension

Contraindications

Organ-transplant recipients

Active autoimmune disease

Immunosuppressant therapy

Pregnancy or breastfeeding

Acute febrile infection

Key Interactions

Anticoagulants & antiplatelets (warfarin, aspirin, clopidogrel)

Antihypertensives, diuretics & lithium (lisinopril, losartan, hydrochlorothiazide)

CYP3A4 substrates (simvastatin, atorvastatin, amlodipine)

Immune-stimulating botanicals (echinacea, ginseng, codonopsis, eleuthero)

Blood-pressure-lowering supplements (magnesium, potassium, garlic, CoQ10)

Risk & Side Effects

High: Mild gastrointestinal effects

Medium: Immune activation in autoimmune and transplant contexts; interaction with immunosuppressant therapy

Low: Allergic and hypersensitivity reactions; hypotension, headache, and fatigue

Speculative: Theoretical long-term oncogenic risk; contamination and species misidentification

Monitoring

Marker	Target	Why
hs-CRP	< 1.0 mg/L	Systemic inflammation, a primary target
CBC with differential	Lymphocytes within reference; stable CD4/CD8	Immune-modulating effect
eGFR	> 90 mL/min/1.73m²	Kidney filtration
Urine albumin-to-creatinine ratio	< 10 mg/g	Early kidney-damage marker
ALT / AST	< 25 U/L	Liver safety
Fasting glucose / HbA1c	70–85 mg/dL; < 5.4%	Metabolic context
Blood pressure	< 120/80 mmHg	Additive hypotensive effect
Leukocyte telomere length (optional)	Track trend	Directly tests the longevity claim

Cadence: Re-test inflammatory and renal markers at 3 months, then every 6–12 months; check blood pressure and interacting-drug levels more frequently early on.

Qualitative Assessment

Subjective energy and reduced fatigue
Frequency and duration of common infections (colds, flu-like illness)
General sense of resilience during stress or seasonal challenge
Absence of digestive intolerance, headache, or lightheadedness signalling poor tolerance

Astragalus for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment